El interés en corto de NewGenIvf Group da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de NewGenIvf Group. Los datos de interés en corto se actualizan cada dos semanas.

NewGenIvf Group (NASDAQ:NIVF) Bolsa, Informe de interés en corto

NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group Ltd

With this transition, Avanos will manage all sales, support, and distribution directly, reinforcing its dedication to delivering high-quality enteral feeding solutions.
For the past 29 years, Vygon UK, a supplier of surgical and medical devices has been a valued distributor of the MIC&#x2A; and MIC-KEY family of products.

AVNS

Avanos Medical Plans To Take Direct Responsibility For Sales And Distribution Of Its MIC-KEY Enteral Feeding Products In UK, Effective July 25, 2025

Norwegian Cruise Line Holdings &nbsp;and NCL Corporation Ltd., a subsidiary of the Company ("NCLC"), announce that NCLC has entered into individually negotiated note exchange agreements with certain existing holders (the "Holders") of NCLC's 5.375% Exchangeable Senior Notes due 2025 (the "2025 Notes"), pursuant to which NCLC and the Holders have agreed to exchange (the "Exchange") $285,425,000 in aggregate principal amount of the Holders' 2025 Notes for (i) $285,425,000 in aggregate principal amount of NCLC's newly issued 0.875% Exchangeable Senior Notes due 2030 (the "2030 Notes") and (ii) an aggregate cash payment (the "Cash Payment") of $51,624,820, plus accrued and unpaid interest on the 2025 Notes to be exchanged to, but excluding, the closing date of the Exchange. The Cash Payment will be equal to the proceeds from the concurrent Equity Offering, as described below, and represents the remainder of NCLC's exchange obligation in excess of the aggregate principal amount of the 2025 Notes to be exchanged.
Concurrently, the Company announces a registered direct offering of 2,708,533 ordinary shares to the Holders at a price of $19.06 per share (the "Equity Offering" and together with the Exchange, the "Transactions"). The Company expects to use the proceeds from the Equity Offering to make the Cash Payment.

NCLH

NCLH To Cut Fully Diluted Share Count By 12.5M Following Note Exchange And Equity Sale

Telsey Advisory Group analyst Dana Telsey maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Outperform and maintains $90 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Outperform on PVH, Maintains $90 Price Target

PROP

Prairie Operating Co. Launches 11-Well Development Program At Rusch Pad In Colorado's DJ Basin

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Buy and maintains $10 price target.

Reiteration

AQST

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

CRGO

Freightos Expands With Air Europa Partnership, Enhancing Digital Freight Booking Across Spain-Latin America Routes

Telsey Advisory Group analyst Dana Telsey maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Outperform and maintains $23 price target.

LEVI

Telsey Advisory Group Maintains Outperform on Levi Strauss, Maintains $23 Price Target

Financial Outlook
BlackBerry is providing the following guidance for the first fiscal quarter and the full fiscal year 2026 (ending February 28, 2026).
<figure class="table"> 
<table>
<tbody>
<tr>
<td>&nbsp;</td>
<td>Q1 FY26</td>
<td>Full fiscal year FY26</td>
</tr>
<tr>
<td>Total BlackBerry revenue:</td>
<td>$107 - $115 million</td>
<td>$504 - $534 million</td>
</tr>
<tr>
<td>QNX revenue:</td>
<td>$51 - $55 million</td>
<td>$250 - $270 million</td>
</tr>
<tr>
<td>Secure Communications revenue:</td>
<td>$50 - $54 million</td>
<td>$230 - $240 million</td>
</tr>
<tr>
<td>Licensing revenue:</td>
<td>Approximately $6 million</td>
<td>Approximately $24 million</td>
</tr>
<tr>
<td>QNX segment adjusted EBITDA:</td>
<td>$2 - $6 million</td>
<td>$55 - $60 million</td>
</tr>
<tr>
<td>Secure Communications segment</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>adjusted EBITDA:</td>
<td>$3 - $6 million</td>
<td>$34 - $44 million</td>
</tr>
<tr>
<td>Licensing segment adjusted EBITDA:</td>
<td>Approximately $5 million</td>
<td>Approximately $20 million</td>
</tr>
<tr>
<td>Adjusted Corporate Costs:</td>
<td>Approximately $10 million</td>
<td>Approximately $40 million</td>
</tr>
<tr>
<td>Total Company adjusted EBITDA:</td>
<td>Breakeven - $7 million</td>
<td>$69 - $84 million</td>
</tr>
<tr>
<td>Non-GAAP basic EPS:</td>
<td>($0.01) - Breakeven</td>
<td>$0.08 - $0.10</td>
</tr>
<tr>
<td>Operating cash flow (usage)</td>
<td>($20) - ($30) million</td>
<td>Approximately $35 million</td>
</tr>
</tbody>
</table>
</figure>

Guidance

BlackBerry Now Expects FY26 Total Revenue Of $504M-$534M Vs $546.34M Est, Adj EPS Of $0.08-$0.10 Vs $0.10 Est

HC Wainwright &amp; Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) with a Buy and raises the price target from $30 to $42.

MLYS

HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $42

Telsey Advisory Group analyst Dana Telsey maintains Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) with a Market Perform and maintains $15 price target.

Telsey Advisory Group Maintains Market Perform on Macy's, Maintains $15 Price Target

As a result, the company expects first quarter 2025 Adjusted Profit Before Tax&nbsp;in a range of $92.3 to $97.3 million (Q1 2024: $67.7 million).
 &nbsp;

Marex Group Expects Q1 Revenues $449.3M - $464.3M, Est $421.573M; Adj EPS Of $0.88 - $0.93, Est $0.77

BRKR

Bruker Announces Introduction Of d-DNP Polarizer For MRI Research And For Dynamic Nuclear Polarization Liquids NMR

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) with a Buy and maintains $32 price target.

SRZN

HC Wainwright & Co. Reiterates Buy on Surrozen, Maintains $32 Price Target

Republic National Distribution Company opens new distribution channels in six states including California, one of the largest markets in the U.S.

Innovation Beverage Group Expands U.S. Reach With Republic National Distribution Company Distribution Deal

Ziff Davis Acquires theSkimm And Maxroll In Q1 To Expand Global Reach And Product Portfolio

HC Wainwright &amp; Co. analyst Mitchell Kapoor upgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Sell to Neutral and maintains the price target from $75 to $75.

Upgrades

SRPT

HC Wainwright & Co. Upgrades Sarepta Therapeutics to Neutral, Maintains Price Target to $75

BlackBerry Expects Q1 Total Revenue Of $107M-$115M Vs $127.99M Est, Adj EPS Of $(0.01)-Breakeven Vs $0.01 Est

DASH

Domino's Partners With DoorDash For Nationwide U.S. Launch In May 2025, Expanding To Canada Later

D. Boral Capital analyst Jesse Sobelson maintains PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) with a Buy and maintains $1.5 price target.

D. Boral Capital Maintains Buy on PEDEVCO, Maintains $1.5 Price Target

Renews highly coveted and valuable hockey rights long term Will deliver more national games and fewer blackouts to hockey fans Rogers is proud to remain the home of NHL&nbsp;hockey

NHL And Rogers Extend National Media Rights Partnership With 12-Year, $11B Agreement

Press Releases

NewGen Progresses Reverse Merger Plans with Engagement of Legal Teams and Updated Timeline

General

NewGen Launches Innovative Lifetime Egg Freezing Service to Address Growing Market Need in Asia

Health Care

NewGen Announces Strategic Acquisition of MicroSort Reproductive Technology

NewGen Announces Reverse Stock Split

Management

NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director

NewGen Issues Clarification on Press Release Titled "NewGen Receives Continued Nasdaq Listing Approval and Announces New Business Development Director" dated February 20, 2025

NewGen Regains Compliance with Nasdaq Minimum Bid Price Requirement and Announces Listing Transfer to the Nasdaq Capital Market

NewGen and BOBCARE Announce Strategic Collaboration to Expand Fertility Services in Kyrgyzstan

NewGenIvf Provides Update on Proposed Reverse Merger with European Wellness Holdings and Completion of Strategic Acquisition of MicroSort Reproductive Technology

NewGenIVF Announces Termination of Proposed Reverse Merger Transaction with European Wellness

American Shared Hospital Services Common Stock

American Shared Hospital

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Kindly MD

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

Comments

NewGenIvf Group

Interés en corto

NewGenIvf Group (NASDAQ:NIVF) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL